Investors

Press Releases

All Releases

View Summary EYLEA® (aflibercept) Injection Approved for the Treatment of Wet Age-Related Macular Degeneration in Europe
Nov 27, 2012
PDF 18.7 KB Add to Briefcase
View Summary ZALTRAP® (ziv-aflibercept) Receives CHMP Positive Opinion in the European Union for Previously Treated Metastatic Colorectal Cancer
Nov 16, 2012
PDF 24.3 KB Add to Briefcase
View Summary Regeneron Announces November 2012 Investor Conference Presentations
Nov 6, 2012
PDF 9.7 KB Add to Briefcase
View Summary Sanofi and Regeneron Announce Patient Enrollment in Cardiovascular Outcomes Trial with Antibody to PCSK9 for Hypercholesterolemia
Nov 5, 2012
PDF 21.6 KB Add to Briefcase
View Summary Sanofi and Regeneron Announce Publication of Phase 2 Results with LDL Cholesterol-Lowering PCSK9 Antibody in the New England Journal of Medicine
Oct 31, 2012
PDF 19.6 KB Add to Briefcase
View Summary Regeneron Reports Third Quarter 2012 Financial and Operating Results
Oct 24, 2012
PDF 30.9 KB Add to Briefcase
View Summary Regeneron Announces Publication of EYLEA® (aflibercept) Injection Phase 3 VIEW 1 and VIEW 2 Studies in Ophthalmology
Oct 18, 2012
PDF 18.3 KB Add to Briefcase
View Summary Regeneron to Report Third Quarter 2012 Financial and Operating Results and Host Conference Call and Webcast on October 24, 2012
Oct 10, 2012
PDF 9.5 KB Add to Briefcase
View Summary EYLEA® (aflibercept) Injection Approved for the Treatment of Wet Age-Related Macular Degeneration in Japan
Sep 28, 2012
PDF 19.9 KB Add to Briefcase
View Summary Regeneron Announces FDA Approval of EYLEA® (aflibercept) Injection For Macular Edema Following Central Retinal Vein Occlusion
Sep 21, 2012
PDF 18.3 KB Add to Briefcase
View Summary Regeneron Named World's #1 Biopharmaceutical Employer in Science Magazine Annual Survey
Sep 21, 2012
PDF 10.8 KB Add to Briefcase
View Summary EYLEA® (aflibercept) Injection Recommended for Approval for the Treatment of Wet Age-Related Macular Degeneration in Europe
Sep 21, 2012
PDF 18.5 KB Add to Briefcase
View Summary Regeneron Announces September 2012 Investor Conference Presentations
Aug 29, 2012
PDF 9.7 KB Add to Briefcase
View Summary U.S. FDA Approves ZALTRAP® (ziv-aflibercept) After Priority Review for Previously Treated Metastatic Colorectal Cancer
Aug 3, 2012
PDF 76.6 KB Add to Briefcase
View Summary Regeneron Receives Complete Response Letter From FDA for ARCALYST® (rilonacept) sBLA for the Prevention of Gout Flares in Patients Initiating Uric Acid-lowering Therapies
Jul 30, 2012
PDF 13.4 KB Add to Briefcase
View Summary Regeneron Reports Second Quarter 2012 Financial and Operating Results
Jul 25, 2012
PDF 29.8 KB Add to Briefcase
View Summary Sanofi and Regeneron Launch Comprehensive Phase 3 Clinical Program With LDL Cholesterol-Lowering PCSK9 Antibody
Jul 20, 2012
PDF 22.2 KB Add to Briefcase
View Summary Regeneron to Report Second Quarter 2012 Financial and Operating Results and Host Conference Call and Webcast on July 25, 2012
Jul 11, 2012
PDF 9.5 KB Add to Briefcase
View Summary Regeneron Announces June 2012 Investor Conference Presentations
May 30, 2012
PDF 9.8 KB Add to Briefcase
View Summary Sanofi and Regeneron Announce Publication of Positive Phase 2 Results for Lipid-Lowering PCSK9 Antibody in The Lancet
May 26, 2012
PDF 22.0 KB Add to Briefcase
Showing 101-120 of 252 Page: 1 2 3 4 5 6 7 8 9 10 ... 13  Previous 20 | Next 20
Add to Briefcase = add release to Briefcase


Close
Form content here please :)